Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline’s additional pipeline candidates include felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing) and SL-1001 (RET kinase inhibitor, IND-enabling studies ongoing). On the other hand, the stock currently carries a Zacks Rank of #3. As it relates to biotechnology stocks, there are a number of factors that have the ability to lead to price movement in the market. About CD123 Under the terms of the agreement, Stemline shareholders will have the right to receive (i) $11.50 in cash plus (ii) one contingent value right for each share of Stemline common stock owned. About BPDCN We are investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Stemline Therapeutics, Inc. (“STML” or the “Company”) (NASDAQ: STML) in connection with the proposed acquisition of the Company by Menarini Group (“Menarini”), a privately-held pharmaceutical company based in Italy. The New York-based oncology-focused, commercial-stage biopharma Stemline Therapeutics Inc (NASDAQ: STML) ringed in merger Monday with a go-private deal valued at up to $667 million. About Stemline Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware: 001-35619: 45-0522567 (State or other Jurisdiction. About Menarini The addition of ELZONRIS, which has potential to treat many other malignancies, as well as the other attractive pipeline assets augments our research and development capabilities and will accelerate our efforts to deliver novel oncology therapeutics to patients in need.”. While Stemline Therapeutics employees earn an average yearly salary of $44,572, different roles can command different wages. ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN. Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the. Stemline Therapeutics (STML) was incorporated under the laws of the State of Delaware in August 2003. Eleventh Floor. The Company offers research, discovery, and development of novel compounds that target cancer stem cells. The World Health Organization (WHO) termed this disease “BPDCN” in 2008; previous names included blastic NK cell lymphoma and agranular CD4+/CD56+ hematodermic neoplasm. File No.) The stock, one that is focused in the biotech space, is presently trading at $14.55 after climbing 11.67% so far today. In terms of biotechnology stocks, there are a number of aspects that have the ability to lead to price movement in the market. In addition, CD123+ cells have been detected in the tumor microenvironment of several solid tumors as well as in certain autoimmune disorders including cutaneous lupus and scleroderma. FLORENCE, Italy and NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, (Nasdaq: STML) today announced a definitive agreement under which … The diagnosis of BPDCN is based on the immunophenotypic diagnostic triad of CD123, CD4, and CD56, as well as other markers. This has resulted in an Earnings ESP of -1.70%. ELZONRIS (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash consideration up to $677 million on a fully diluted basis. Questions for the Investor Relations Department can be submitted through the form below. STEMLINE THERAPEUTICS. About Stemline. Stemline Contacts. treatment of adult and pediatric patients, two years and older, with BPDCN. About Stemline. (I.R.S. CD123 has also been reported on multiple myeloma (MM), acute lymphoid leukemia (ALL), hairy cell leukemia (HCL), Hodgkin’s lymphoma (HL), and certain Non-Hodgkin’s lymphomas (NHL). The higher paying positions at Stemline Therapeutics include physician, hospitalist, staff pharmacist, and respiratory therapist. Tel. To receive more information regarding the investigation of Stemline Therapeutics, Inc. please fill out the form below. development and commercialization of novel oncology therapeutics. Andrew Cole / Gloria Labbad (U.S.) Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. treatment of adult and pediatric patients, two years and older, with BPDCN. For investor and media inquiries, please contact: Stemline launched ELZONRIS for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients, two years or older, following the approval by the United States Food and Drug Administration in December 2018. tagraxofusp-erzs BL 761116. BPDCN typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera. SECTOR. FLORENCE, Italy-- (BUSINESS WIRE)--Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash … In parallel, Stemline has been evaluating ELZONRIS in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and others. Menarini acquired Stemline for an upfront payment of $11.50 per share in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 per share in cash upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval. Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. Stemline Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: Pursuant to Sections 141(f) and 242 of the DGCL, the Board of Directors of the Corporation (the “Board” Agreements and Contracts. For Stemline Therapeutics, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. The Menarini Group is a leading international pharmaceutical company with a presence in over 100 countries, including a direct presence in over 70 countries. : +49 30 6707-0 Email: menarini-svc@sardverb.com, KONTAKT Additional pipeline candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), and SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing). About ELZONRIS® CD123 is a cell surface target expressed on a wide range of malignancies including blastic plasmacytoid dendritic cell neoplasm (BPDCN), certain myeloproliferative neoplasms (MPNs) including chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF), acute myeloid leukemia (AML) (and potentially enriched in certain AML subsets), myelodysplastic syndrome (MDS), and chronic myeloid leukemia (CML). Its global platform extends throughout Europe, Central America, Africa, the Middle East and Asia and generates over $4.2 billion in annual sales. Stemline Therapeutics, Inc. (STML) is working its way for to the bottom in the market in today’s trading session. ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with BPDCN. Stemline Therapeutics, Inc. (STML) is working its way for to the top in the market today. 750 Lexington Avenue. STEMLINE THERAPEUTICS, INC. : Financial news and information Stock STEMLINE THERAPEUTICS, INC. | Nasdaq: | Nasdaq The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. Shares of Stemline Therapeutics (NASDAQ:STML) are up 153% to $12.02 at 1:11 p.m. EDT after the company announced it is being acquired by a … On May 3, 2020, Stemline Therapeutics, Inc., a Delaware corporation (“Stemline”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Berlin-Chemie AG, a company formed under the laws of Germany (“Berlin-Chemie”), and Mercury Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Berlin-Chemie (“Purchaser”). Deutsche Bank AG lessened its holdings in shares of Stemline Therapeutics Inc (NASDAQ:STML) by 71.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). FDA Approved Biologics and Pending Applications. Investor Relations Peter McDonald Stemline Therapeutics, Inc. 646-502-2307 Email: pmcdonald@stemline.com. Stemline’s lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. Employer. Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. Charlie Chichester / Camilla Scassellati-Sforzolini (Europe) The firm owned 16,297 shares of the biopharmaceutical company’s stock after selling 40,437 shares during the period. The BPDCN cell of origin is the plasmacytoid dendritic cell (pDC) precursor. FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash … In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). Media Andy Brimmer / … Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company and a leading developer of novel oncology compounds directed to cancer stem cell targets. NEW YORK , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that management will present at the 38 th Annual J.P. Stemline is a commercial-stage biopharmaceutical company committed to applying our scientific leadership and commercial expertise to transform the lives of patients with cancer. ELZONRIS® (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN. Stemline Therapeutics Inc. provides biopharmaceutical services. For more information, please visit the BPDCN disease awareness website at www.bpdcninfo.com. ELZONRIS® (tagraxofusp), a. targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the. Identification No.) Search for: Filter Results. Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33% Stemline's lead drug dazzles in a pivotal-stage study, but investors … Elzonris. of Incorporation) (Commission. Stemline Therapeutics, Inc. related to its sale to Berlin-Chemie AG. Menarini is also committed to oncology, with several new investigational drugs in development for the treatment of a variety of tumors. STEMLINE THERAPEUTICS. For over 125 years, Menarini has been investing in the development and distribution of pharmaceuticals to serve patients and physicians around the world with a full portfolio of products in the cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to … Deutsche Bank AG’s holdings […] development and commercialization of novel oncology therapeutics. The Company's lead compound, SL-401, targets the interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. Or Search By: Brand Name. Stemline Therapeutics Inc is a clinical-stage biopharmaceutical company. FLORENCE, Italy-- (BUSINESS WIRE)--Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has … Sard Verbinnen & Co For full prescribing information in the U.S., visit www.ELZONRIS.com. ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). The transaction, which was announced on 4 May 2020, strengthens Menarini’s oncology portfolio with the addition of both commercial and clinical-stage assets. It is the only FDA-approved … The company, one that is focused in the biotechnology space, is currently priced at $13.70 after a move down of -5.12% so far in today’s session. Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. FLORENCE – June 10, 2020 – Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced that is has successfully completed the acquisition of Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics (Nasdaq: STML), for an aggregate cash … Anfahrt: » Wie Sie uns erreichen, Nachhaltigkeit & gesellschaftliches Engagement, Fachinformationen Gebrauchsinformationen Schulungsmaterialen, BERLIN-CHEMIE unterstützt Berliner COVID-19 Impfzentren, 100 Tage Gesundheitspolitik zum Hören – Das Gesundheitsmanagement zieht Bilanz zum wöchentlichen EinBlick-Podcast, CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Menarini Group: Engagement im Kampf gegen die heutige COVID-19-Pandemie mit dem Ziel, ähnliche Gesundheitskrisen in Zukunft abzuwenden, Acquisition of Stemline establishes Menarini’s presence in the U.S. biopharmaceutical oncology market, Menarini will support further development of Stemline’s ELZONRIS® and enable global expansion by leveraging its commercial infrastructure in Europe and other ex-U.S. geographies, Following the transaction, Menarini will continue to research ELZONRIS in additional CD123-expressing indications. ELZONRIS is also being evaluated in additional clinical trials in other CD123+ indications, including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF), acute myeloid leukemia (AML), and others are planned including a CD123+ all-comers trial. Stemline is developing three clinical stage product candidates, SL-401, SL-701, and SL-801. ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123), a target present on a wide range of malignancies. Elcin Barker Ergun, CEO of Menarini Group, commented, “We are very excited to complete the acquisition of Stemline and to welcome their accomplished team to Menarini. Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the. Abrilada Actemra® Acthrel® Actimmune® Activase® / Cathflo® Activase® Adcetris® Adlyxin® Admelog® Afrezza® Aimovig Ajovy® Aldurazyme® Alferon N Injection® Amjevita Amphadase® … A worker with the title physician salary at Stemline Therapeutics can earn an average yearly salary of $246,393. The company is involved in the business of discovering, acquiring and developing and commercializing therapeutics for oncology indications of unmet medical need. BPDCN, formerly blastic NK-cell lymphoma, is an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes. © 2021 – Stemline Therapeutics, Inc. All rights reserved | Privacy & Terms of Use. … Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. * Required fields Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS® (tagraxofusp), a. targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the. BERLIN-CHEMIE AG - Glienicker Weg 125 - 12489 Berlin - Deutschland
Freiheit Und Determination Freud, Username Gute Tiktok Namen, Direktes Zitat Fußnote Vor Oder Nach Punkt, Niko Griesert Wohnort, Word Literaturverzeichnis Mit Citavi Verknüpfen, Dua Für Gesundheit, Dynaudio Special Forty Preis, Preiser Figuren 1:24, Sms Von Amazon Spam, Warum Ist Der Wettbewerb In Einer Marktwirtschaft Wichtig,